drugset / Trial / NCT00520949

Quadruple Therapy for Triple Therapy Resistant Helicobacter Pylori Infection

NCT00520949

Completed 176 enrolled Aga Khan University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Triple therapy, a combination of proton pump inhibitor with two antibiotics, is the gold standard for anti-Helicobacter pylori treatment. Usual antibiotics are clarithromycin, and either amoxicillin or one of the nitroimidazoles (metronidazole). However, there is an increasing evidence of H. pylori resistance to classical triple therapy. Another reason for this failure being low patient compliance with treatment. A regimen useful in one geographical area may not be effective or practical in another area. The aim of this study was to eradicate H. pylori infection resistant to triple therapy, establish the efficacy and safety of a 14-day therapeutic regimen to eradicate of H. pylori in patients who have failed with the classical triple therapy (omeprazole, clarithromycin and amoxicillin) given for 14 days.

Timeline

Start
2006-10
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 1 g
Subject BISMUTH SUBCITRATE Small molecule 240 mg
Subject Esomeprazole Small molecule 40 mg
Subject Furazolidone Small molecule 200 mg

Indications

No indication recorded.